Citizens National Bank Trust Department Sells 1,630 Shares of CVS Health Co. (NYSE:CVS)

Citizens National Bank Trust Department lowered its stake in CVS Health Co. (NYSE:CVS) by 36.4% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,845 shares of the pharmacy operator’s stock after selling 1,630 shares during the quarter. Citizens National Bank Trust Department’s holdings in CVS Health were worth $179,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the stock. Fort L.P. acquired a new position in shares of CVS Health in the 3rd quarter valued at $202,000. Van ECK Associates Corp lifted its stake in shares of CVS Health by 17.2% in the 3rd quarter. Van ECK Associates Corp now owns 516,095 shares of the pharmacy operator’s stock valued at $32,452,000 after purchasing an additional 75,805 shares during the period. New Covenant Trust Company N.A. lifted its stake in shares of CVS Health by 15.4% in the 3rd quarter. New Covenant Trust Company N.A. now owns 4,170 shares of the pharmacy operator’s stock valued at $256,000 after purchasing an additional 558 shares during the period. Investors Asset Management of Georgia Inc. GA ADV lifted its stake in shares of CVS Health by 6.0% in the 3rd quarter. Investors Asset Management of Georgia Inc. GA ADV now owns 10,721 shares of the pharmacy operator’s stock valued at $674,000 after purchasing an additional 609 shares during the period. Finally, Greenwich Wealth Management LLC lifted its stake in shares of CVS Health by 3.9% in the 3rd quarter. Greenwich Wealth Management LLC now owns 24,557 shares of the pharmacy operator’s stock valued at $1,544,000 after purchasing an additional 922 shares during the period. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Trading Down 1.2 %

CVS Health stock opened at $55.81 on Monday. CVS Health Co. has a 52 week low of $52.77 and a 52 week high of $83.25. The company has a debt-to-equity ratio of 0.83, a quick ratio of 0.66 and a current ratio of 0.86. The stock has a market capitalization of $70.21 billion, a P/E ratio of 9.93, a PEG ratio of 0.83 and a beta of 0.55. The stock has a 50-day simple moving average of $59.66 and a 200 day simple moving average of $59.49.

CVS Health (NYSE:CVS) last posted its quarterly earnings results on Wednesday, August 7th. The pharmacy operator reported $1.83 EPS for the quarter, topping analysts’ consensus estimates of $1.73 by $0.10. The business had revenue of $91.23 billion during the quarter, compared to analysts’ expectations of $91.41 billion. CVS Health had a return on equity of 12.72% and a net margin of 1.98%. CVS Health’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter last year, the company posted $2.21 earnings per share. Analysts expect that CVS Health Co. will post 6.41 earnings per share for the current year.

CVS Health Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, November 1st. Shareholders of record on Monday, October 21st were given a dividend of $0.665 per share. The ex-dividend date of this dividend was Monday, October 21st. This represents a $2.66 annualized dividend and a yield of 4.77%. CVS Health’s dividend payout ratio (DPR) is presently 47.33%.

Analysts Set New Price Targets

Several analysts recently commented on the company. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $62.00 price objective on shares of CVS Health in a research note on Tuesday, October 1st. Wells Fargo & Company raised their price objective on CVS Health from $60.00 to $61.00 and gave the stock an “equal weight” rating in a research note on Monday, August 12th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $68.00 price objective on shares of CVS Health in a research note on Wednesday, September 4th. TD Cowen raised CVS Health from a “hold” rating to a “buy” rating and raised their price objective for the stock from $59.00 to $85.00 in a research note on Friday, October 4th. Finally, Deutsche Bank Aktiengesellschaft dropped their price objective on CVS Health from $64.00 to $63.00 and set a “hold” rating on the stock in a research note on Friday, August 9th. Nine investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat, CVS Health presently has an average rating of “Moderate Buy” and a consensus target price of $73.17.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.